Category Archives: Generics

Why the US and pharmaceutical giants want a provision in India’s patent law revoked

Source: Scroll.in | May 02, 2018 India’s patent laws are under attack again. This time, too, the target is a provision not commonly found in patent laws elsewhere. This rule requires patent holders to disclose whether they are working their … Continue reading

Posted in Generics, Indian Patent Law, IPR, Patents | Leave a comment

Will the Trump tariffs on China raise drug prices for Americans?

by Ed Silverama, StatNews | April 4, 2018 Now that the Trump administration has proposed 25 percent tariffs on thousands of Chinese-made products, including raw ingredients for a slew of medicines, there are concerns that prices for these products may rise, … Continue reading

Posted in Drug prices, Generics, Uncategorized | Leave a comment

Novartis must end ‘bullying tactics’ over life-saving medicines, campaigners says

Global protests ahead of Novartis AGM in Switzerland tomorrow Call for new CEO to clean up company following scandals in Colombia and Greece Thursday 1 March 2018 – Swiss multinational Novartis today faced international calls from an alliance of health … Continue reading

Posted in Compulsory Licensing, Generics, Novartis Case, Uncategorized | Leave a comment

Health groups irked by Supreme Court order on vaccine PSUs; mull fresh petition

on behalf of the All India Drug Action Network (AIDAN) and co-petitioners 19 February 2018 Several health groups expressed their strong disappointment with the order of the Supreme Court (SC) of February 12, 2018, which refused to review or recall … Continue reading

Posted in Generics, Uncategorized | Leave a comment

Cancer Drug Price Rises 1, 400% With No Generic to Challenge It

By Peter Loftus, Wall Street Journal Since 2013, the price of a 40-year-old, off-patent cancer drug in the U.S. has risen 1,400%, putting the life-extending medicine out of reach for some patients. Introduced in 1976 to treat brain tumors and Hodgkin … Continue reading

Posted in Cancer, Drug prices, Generics, Price hikes, Uncategorized | Leave a comment

India to oppose anti-generics proposals at RCEP meet

Source: LiveMint India stands firm in opposing proposals that could hinder global access to affordable generic drugs and life-saving vaccines South Korea and Japan have been pushing for proposals to extend drug and vaccine patent terms, a move that is … Continue reading

Posted in Data Exclusivity, Generics, Patent, Patent Term Extension, Regional Comprehensive Economic Partnership, TRIPS, TRIPS plus, TRIPS&IP rights, Uncategorized, WTO | Leave a comment

Global access to affordable medicines should not be restricted

MSF has witnessed the negative impact of monopoly pricing on life-saving medicines and vaccines in its medical projects all over the world. Courtesy- ajp.com.au As 16 countries negotiating the Regional Comprehensive Economic Partnership (RCEP) agreement meet this week in Incheon, … Continue reading

Posted in Data Exclusivity, Generics, Patent, Patent Term Extension, Regional Comprehensive Economic Partnership, TRIPS&IP rights, Uncategorized, WTO | Leave a comment